Myriad Genetics Inc. has separated from its Chief Commercial Officer, Brian Donnelly, effective September 21, 2026. The departure is part of a separation agreement resulting in a lump sum payment of $1,322,294.
Myriad Genetics Inc. has separated from its Chief Commercial Officer, Brian Donnelly, effective September 21, 2026. The departure is part of a separation agreement resulting in a lump sum payment of $1,322,294.